Discussion on the Cost–Effectiveness Analysis of the CALGB/Alliance Trial and the Use of Zoledronic Acid Generic in Women With Metastatic Breast Cancer - a podcast by American Society of Clinical Oncology (ASCO)

The paper examines the cost-effectiveness of schedules of bone-modifying agents in patients with breast cancer and skeletal metastases and supports the 3-month administration of the generic zoledronic acid in terms of cost and efficacy.

Read the accompanying article on JCO.org.

Further episodes of Journal of Clinical Oncology (JCO) Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)